Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 18Breast Neoplasms 16Leukemia, Myeloid, Acute 15Glioblastoma 13Colorectal Neoplasms 13Prostatic Neoplasms 12Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Lung Neoplasms 9Glioma 8Carcinoma, Hepatocellular 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Head and Neck Neoplasms 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6Myelodysplastic Syndromes 6Hematologic Neoplasms 6Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Melanoma 5Uterine Cervical Neoplasms 4Sarcoma 4Colonic Neoplasms 4Brain Neoplasms 4Solid Tumor 3Small Cell Lung Carcinoma 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

amivantamab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Locally Recurrent Skin Squamous Cell Carcinoma × 1 year × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡